Pieris Pharmaceuticals Inc (PIRS) 3.24 $PIRS 5 Stocks

New Post Public Reply Private Reply Replies (0) Message Board

Jul 28, 2015 at 2:27 PM

Pieris Pharmaceuticals Inc (PIRS) 3.24 $PIRS

5 Stocks Under $10 Set to Soar -- Must-See Charts
at The Street - Thu Jul 16, 10:19AM CDT
Here's a technical look at how to trade five stocks under $10 that look to be setting up to break out.
PIRS: 3.24 (+0.05), MBII: 1.91 (-0.01), ESI: 5.14 (+0.24), SYRX: 1.73 (+0.01), BLFS: 2.20 (+0.04)

OTC Markets Group Announces Second Quarter 2015 Index Performance and Rebalancing
PR Newswire - Thu Jul 16, 6:00AM CDT
OTC Markets Group Inc. ("OTC Markets Group" or "the Company"

(OTCQX: OTCM) today announced the second quarter 2015 performance and quarterly rebalancing of the OTCQX® indexes, the OTCQB® Venture Index, the OTCM QX ADR Index ("OTCQX30"

and the OTCM ADR Index.
CETX: 2.88 (-0.03), PIRS: 3.24 (+0.05), RELY: 11.13 (-0.14), CRBP: 2.06 (+0.01), ONCS: 6.29 (+0.26), CYNA: 16.54 (+0.02), BPMX: 2.34 (+0.22), CXRX: 79.73 (+1.72)

Pieris to Receive Seventh Milestone Payment From Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
Marketwired - Wed Jul 08, 7:02AM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary AnticalinÂ® biotherapeutic technologies, announced today it will receive its third milestone payment for the second program in its discovery and development collaboration with Daiichi Sankyo Company, Limited ("Daiichi Sankyo"

, and seventh milestone payment overall under the multi program collaboration. The amount of payment was not disclosed. The payment was triggered by the achievement of positive in vivo proof of concept data and progression of the Anticalin drug candidate through a non-GLP toxicity study in non-human primates.
PIRS: 3.24 (+0.05)

Pieris Pharmaceuticals Closes Public Offering of Common Stock
Marketwired - Mon Jul 06, 2:59PM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary AnticalinÂ® biotherapeutic technologies, today announced the closing of a public offering of 9,090,909 shares of its common stock at a public offering price of $2.75 per share.
PIRS: 3.24 (+0.05)

Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 8:19AM CDT

FIT: 45.65 (+1.72), PIRS: 3.24 (+0.05), KITE: 72.15 (+3.29), SRPT: 32.34 (+0.34), WSH: 46.25 (+0.22), CALA: 8.10 (-0.33), CLLS: 36.27 (+1.40), LBIO: 8.94 (+0.15), JUNO: 48.92 (+1.12), PNR: 59.38 (+0.63), APOL: 13.49 (+0.14), DSKX: 3.30 (-0.01)

Pieris Pharmaceuticals Prices Public Offering of Common Stock
Marketwired - Tue Jun 30, 7:02AM CDT
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary AnticalinÂ® biotherapeutic technologies, today announced the pricing of a public offering of 9,090,909 shares of its common stock at a public offering price of $2.75 per share. All shares of common stock are being offered by the company. In addition, Pieris has granted the underwriters a 30-day option to purchase up to an additional 1,363,636 shares of common stock at the same price to cover any over-allotments.
PIRS: 3.24 (+0.05)

Week Ahead: Get Ready For A Dose Of High-Growth Healthcare With 7 IPOs
Renaissance Capital IPO Research - Seeking Alpha - Mon Jun 29, 1:40AM CDT
As many as 7 companies could go public in the US during the shortened holiday week. The week's three high-growth health care IPOs that are on the IPO calendar should receive the most interest, especially after device maker Glaukos (Pending: GKOS )...
CNXC: 14.87 (+0.20), PIRS: 3.24 (+0.05), TDOC: 30.84 (-0.47), CFMS: 22.60 (-0.53), NTRA: 18.01 (+0.01)

Week Ahead: As Many As 16 IPOs Could Price During The Week Of June 22
Renaissance Capital IPO Research - Seeking Alpha - Mon Jun 22, 10:31AM CDT
16 companies are on the calendar to go public this week and raise $2.5 billion. It should be the year's most active week in the IPO market; the second busiest week saw 10 IPOs in January. Investors have plenty of options this week, so expect IPO...
TRU: 24.45 (+0.06), PIRS: 3.24 (+0.05), CATB: 12.88 (+0.88), WNFM: (), GKOS: 30.17 (-0.44), APPF: 14.55 (+0.40), LNTH: 6.54 (+0.01), YECO: 3.85 (-0.18), MCRN: 19.39 (+0.34), ALRM: 17.21 (+0.06), MCRB: 36.27 (+1.22)

Pieris Pharmaceuticals on deck for IPO and uplisting
Seeking Alpha - at Seeking Alpha - Fri Jun 19, 3:39PM CDT

PIRS: 3.24 (+0.05)

Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia
Marketwired - Wed Jun 10, 7:02AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary AnticalinÂ® biotherapeutic technologies, announced today the completion of enrollment of healthy subjects in a blinded, placebo-controlled Phase I clinical trial for the Company's PRS-080 program, a hepcidin antagonist to treat anemia. This study was conducted at a single site in Germany.
PIRS: 3.24 (+0.05)

Recent News Highlights Pieris's Efforts In Immuno-Oncology
Jason Napodano, CFA - at Seeking Alpha - Fri May 22, 6:36AM CDT

PIRS: 3.24 (+0.05)

Pieris Pharmaceuticals to Present Data on Novel Anti-CD137 and HER2 Bispecific Immuno-Oncology Program at UBS Global Healthcare Conference
Marketwired - Tue May 19, 6:31AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary AnticalinÂ® biotherapeutic technologies, announced today that President and CEO, Stephen Yoder, will present preclinical data on a new immuno-oncology program -- an Anticalin-based CD137-HER2 bispecific -- at the UBS Global Healthcare Conference at 4:30 pm EDT.
PIRS: 3.24 (+0.05)

Pieris Pharmaceuticals Appoints Immuno-Oncology Expert, Holbrook Kohrt, M.D., Ph.D., to Spearhead Immuno-Oncology Efforts and Initiates Research Collaboration With Leading Cancer Research Center
Marketwired - Thu May 14, 7:30AM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its patented and proprietary AnticalinÂ® biotherapeutic technologies, announced today that it has engaged Dr. Holbrook Kohrt, M.D., Ph.D. as Senior Advisor Translational Medicine Immuno-oncology.
PIRS: 3.24 (+0.05)

Pieris Pharmaceuticals Reports First Quarter 2015 Financial Results
Marketwired - Wed May 13, 4:30PM CDT
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary AnticalinÂ® biotherapeutic technologies, reported today financial results for the first quarter ended March 31, 2015 and provided an update on the Company's recent developments.
PIRS: 3.24 (+0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Athlete Threats: Public Info Fuels Security Risks

Public Exposure: The New Athlete Achilles' Heel Imagine sitting on millions while living in a glass house. That's the kind of predicament today's athletes find themselves in, thanks to the treasure trove of public information spilling their personal lives all over the internet. According to the latest Hush Intelligence Athlete Threat Report 2026, this very exposure has...

Ace Hardware Ups the Stakes with Rewards Days Event

Ace Hardware: Doubling Down with Rewards Ace Hardware's rolling out the red carpet for its loyal customers. Imagine this: exclusive deals on trusted brands and double points on purchases—an incentive any savvy shopper would jump at. From October 6 to 7, those in the Ace Rewards circle have the chance to nab some hefty savings and perks, a move that's more than just a...

New Tools Arm Manufacturers in Additive Arena

Diving Headfirst into Additive Manufacturing Standards Additive manufacturing (AM)—it's not just another tech buzzword. It's revolutionizing everything from life-saving medical devices to cutting-edge aerospace components. But as with any game-changing innovation, there's a wild west era before standards reign in the chaos. Enter ANSI and America Makes, offering new...

Nukleus Launches Unified Platform for Athletes' Business

Leveling the Business Field for Athletes Athletes spend their lives fighting for every inch on the field, and now Nukleus is giving them the tools to hold ground off it. Why should they be the last ones to know their own business? Ashton Jeanty and Nukleus got tired of that narrative and kicked off a platform today with a real promise: putting an athlete's entire business...

Gateway Unveils All-In-One Award Travel Platform

Transforming Loyalty with point.me's Gateway Here's the deal: the loyalty program game just changed. Point.me rolled out this slick beast called Gateway, and it's weaving award travel booking right into your everyday banking apps. That's right, ditch those clunky third-party sites, because now you can browse, compare, transfer, and book your award travel directly from...

MiniCo's New Desk: A Game Changer for E&S Market

A New Chapter in Industrial Casualty Look out, folks! MiniCo Insurance Agency is making waves with its latest launch. They're teaming up with Lloyd's of London, not to sell fish and chips, but to bring something groundbreaking in the insurance space—an industrial casualty trading desk. And if you’re raising an eyebrow wondering why this matters, let me break it down...

Sports Research Joins Costco: Creatine Mix Available

Breaking Into the Big League: Sports Research Hits Costco When a company's product finds its way onto Costco's shelves, you know they're not just playing in the minor leagues anymore. This October, Sports Research® made a bold move into the retail giant's sports nutrition section with their new Creatine + Electrolytes powder. It's not their first rodeo when it comes to...

Fiber Giants Unite to Boost Connectivity in Montana

Montana's Broadband Transformation Takes a Leap Folks in Northwest Montana, take note. Vero Fiber and MontanaSky have tied the knot, officially sealing a merger that doesn't just unite two reputable broadband providers but promises to shake up the internet game across the region. Just ask anyone who's tried to stream a movie during peak hours in Flathead Valley. A...

Wisconsin Chefs Transform Pizza with Crave Brothers Cheese

Reimagining Pizza with Wisconsin's Best Cheeses It's not every day you see a pizza challenge that turns a staple of Friday nights into a gastronomic showcase. But that's exactly what's happening in Wisconsin as chefs flex their creativity using Crave Brothers Farmstead Cheese. This is no ordinary cheese-and-pepperoni affair—these culinary pros are cooking up pizzas with...

Varda Space's Dual Launch Signals Orbital Ambitions

It's not every day you see two commercial rockets heading to orbit on the same ride, but that's precisely what Varda Space Industries just pulled off. With the W-8 and W-9 vehicles blasting off together, Varda is positioning itself for a leap in orbital operations. They've hitched a ride aboard SpaceX's Transporter-18 mission, and this is more than just a double...